ENSG
Neutral signalScored 2026-08-02 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
The Ensign Group, Inc.
- Nom
- The Ensign Group, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Care Facilities
- Bourse
- NASDAQ
- Capitalisation
- $10.3B
- Employés
- 46,000
- PDG
- Barry R. Port
- Site web
- https://ensigngroup.net
- Marché
- AVAHBKDCHECYHEHCHCA
The Ensign Group, Inc. operates as a healthcare provider, primarily concentrating on post-acute care services, alongside other supporting business ventures. The company's activities are organized into two main divisions: Skilled Services and Real Estate. Within its Skilled Services segment, Ensign provides extensive short-term and long-term nursing care tailored for patients recovering from extended illnesses, managing chronic health conditions, or requiring elder care. This division also encompasses a variety of rehabilitative therapies, such as physical, occupational, and speech therapy, among other specialized healthcare provisions. Beyond direct medical care, the company furnishes essential amenities like lodging, customized dietary programs, and opportunities for social engagement, recreation, and entertainment. Ensign additionally manages senior living facilities and delivers convenient mobile diagnostic services. Its diverse array of supplementary services includes digital X-rays, ultrasounds, electrocardiograms, laboratory analyses, sub-acute care, and patient transportation, which can be provided either in patients' residences or at long-term care facilities. The company also engages in the leasing of real estate properties. As of April 4, 2022, Ensign operated a network of 252 healthcare facilities spread across thirteen U.S. states: Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The Ensign Group, Inc. was established in 1999 and is headquartered in San Juan Capistrano, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 867 titres (~152 072,52 $ US)
- Insiders
- Blouin Ann ScottAgwunobi John OParkinson Mark Vincent
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$54,962
Avg sell (VWAP, 90d window) $183.21 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$37,000 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-07-27
- Last synced
-
2026-10-19 22:02:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-16 | Parkinson Mark Vincent | Sell · S | 100 | $179.62 | $17,962 | Form 4 |
| 2026-07-27 | Blouin Ann Scott | Sell · S · 10b5-1 | 200 | $185.00 | $37,000 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-02 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
ENSG shows solid operational momentum with a Q2 earnings beat and a raised 2026 outlook driven by occupancy gains and acquisitions, but the catalyst confidence is moderated (0.7) by ongoing law firm securities…
The first sentence of the analysis written for ENSG on 2026-08-02 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $37K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $37K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 1.42 · operating margin 8.4%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 15.8% | 15.7% | 15.8% | 17.1% | 17.8% | |
| Ebit Margin | 9.2% | 9.3% | 7.5% | 9.9% | 10.1% | |
| Ebitda Margin | 11.2% | 11.2% | 9.5% | 11.9% | 12.2% | |
| Operating Profit Margin | 8.4% | 8.4% | 6.8% | 9.8% | 9.9% | |
| Pretax Profit Margin | 9.0% | 9.1% | 7.3% | 9.6% | 9.8% | |
| Continuous Operations Profit Margin | 6.8% | 7.0% | 5.6% | 7.4% | 7.5% | |
| Net Profit Margin | 6.8% | 7.0% | 5.6% | 7.4% | 7.4% | |
| Bottom Line Profit Margin | 6.8% | 7.0% | 5.6% | 7.4% | 7.4% | |
| Current Ratio | 1.423 | 1.557 | 1.425 | 1.342 | 1.223 | |
| Quick Ratio | 1.423 | 1.557 | 1.425 | 1.342 | 1.223 | |
| Solvency Ratio | 0.139 | 0.135 | 0.105 | 0.130 | 0.137 | |
| Cash Ratio | 0.563 | 0.625 | 0.694 | 0.543 | 0.501 | |
| Price To Earnings Ratio | 29.033 | 25.259 | 29.843 | 23.132 | 23.518 | |
| Price To Earnings Growth Ratio | 2.064 | 0.633 | -3.699 | 1.588 | 1.974 | |
| Forward Price To Earnings Growth Ratio | 2.064 | 0.633 | -3.699 | 1.588 | 1.974 | |
| Price To Earnings Diluted Ratio | 29.829 | 25.949 | 30.742 | 23.952 | 24.550 | |
| Price To Earnings Diluted Growth Ratio | 2.121 | 0.644 | -4.048 | 1.546 | 2.087 | |
| Price To Book Ratio | 4.473 | 4.097 | 4.190 | 4.163 | 4.482 | |
| Price To Sales Ratio | 1.974 | 1.767 | 1.676 | 1.716 | 1.741 | |
| Price To Free Cash Flow Ratio | 26.928 | 39.838 | 23.110 | 28.074 | 22.193 | |
| Price To Operating Cash Flow Ratio | 17.691 | 21.681 | 16.596 | 19.055 | 16.594 | |
| Debt To Assets Ratio | 0.761 | 0.423 | 0.448 | 0.456 | 0.444 | |
| Debt To Equity Ratio | 1.862 | 1.075 | 1.254 | 1.262 | 1.240 | |
| Debt To Capital Ratio | 0.651 | 0.518 | 0.556 | 0.558 | 0.553 | |
| Long Term Debt To Capital Ratio | 0.483 | 0.072 | 0.089 | 0.107 | 0.130 | |
| Financial Leverage Ratio | 2.448 | 2.542 | 2.800 | 2.768 | 2.793 | |
| Working Capital Turnover Ratio | 12.770 | 11.731 | 14.590 | 19.167 | 38.302 | |
| Operating Cash Flow Ratio | 0.631 | 0.467 | 0.513 | 0.468 | 0.527 | |
| Operating Cash Flow Sales Ratio | 0.112 | 0.081 | 0.101 | 0.090 | 0.105 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.657 | 0.544 | 0.718 | 0.679 | 0.748 | |
| Debt Service Coverage Ratio | 37.379 | 31.594 | 24.119 | 23.095 | 24.560 | |
| Interest Coverage Ratio | 53.243 | 43.242 | 31.577 | 33.235 | 38.030 | |
| Short Term Operating Cash Flow Coverage Ratio | 133.492 | 84.970 | 95.358 | 70.181 | 73.320 | |
| Operating Cash Flow Coverage Ratio | 0.136 | 0.176 | 0.201 | 0.173 | 0.218 | |
| Capital Expenditure Coverage Ratio | 2.915 | 2.194 | 3.547 | 3.113 | 3.964 | |
| Dividend Paid And Capex Coverage Ratio | 2.713 | 2.020 | 3.163 | 2.733 | 3.399 | |
| Dividend Payout Ratio | 0.042 | 0.046 | 0.062 | 0.054 | 0.059 | |
| Enterprise Value Multiple | 24.006 | 18.886 | 21.551 | 17.900 | 17.385 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 15.8% | ▲0.1% | ▼-0.7% |
| Ebit Margin | 9.2% | ▼-0.1% | ▼-0.0% |
| Ebitda Margin | 11.2% | -0.0% | ▲0.0% |
| Operating Profit Margin | 8.4% | -0.0% | ▼-0.3% |
| Pretax Profit Margin | 9.0% | ▼-0.1% | ▲0.1% |
| Continuous Operations Profit Margin | 6.8% | ▼-0.2% | ▼-0.1% |
| Net Profit Margin | 6.8% | ▼-0.2% | ▼-0.1% |
| Bottom Line Profit Margin | 6.8% | ▼-0.2% | ▼-0.1% |
| Current Ratio | 1.423 | ▼-0.135 | ▲0.029 |
| Quick Ratio | 1.423 | ▼-0.135 | ▲0.029 |
| Solvency Ratio | 0.139 | ▲0.004 | ▲0.010 |
| Cash Ratio | 0.563 | ▼-0.061 | ▼-0.022 |
| Price To Earnings Ratio | 29.033 | ▲3.775 | ▲2.876 |
| Price To Earnings Growth Ratio | 2.064 | ▲1.431 | ▲1.552 |
| Forward Price To Earnings Growth Ratio | 2.064 | ▲1.431 | ▲1.552 |
| Price To Earnings Diluted Ratio | 29.829 | ▲3.880 | ▲2.824 |
| Price To Earnings Diluted Growth Ratio | 2.121 | ▲1.477 | ▲1.651 |
| Price To Book Ratio | 4.473 | ▲0.376 | ▲0.192 |
| Price To Sales Ratio | 1.974 | ▲0.207 | ▲0.199 |
| Price To Free Cash Flow Ratio | 26.928 | ▼-12.909 | ▼-1.100 |
| Price To Operating Cash Flow Ratio | 17.691 | ▼-3.989 | ▼-0.632 |
| Debt To Assets Ratio | 0.761 | ▲0.338 | ▲0.254 |
| Debt To Equity Ratio | 1.862 | ▲0.787 | ▲0.523 |
| Debt To Capital Ratio | 0.651 | ▲0.133 | ▲0.083 |
| Long Term Debt To Capital Ratio | 0.483 | ▲0.412 | ▲0.307 |
| Financial Leverage Ratio | 2.448 | ▼-0.094 | ▼-0.222 |
| Working Capital Turnover Ratio | 12.770 | ▲1.039 | ▼-6.542 |
| Operating Cash Flow Ratio | 0.631 | ▲0.164 | ▲0.110 |
| Operating Cash Flow Sales Ratio | 0.112 | ▲0.030 | ▲0.014 |
| Free Cash Flow Operating Cash Flow Ratio | 0.657 | ▲0.113 | ▼-0.012 |
| Debt Service Coverage Ratio | 37.379 | ▲5.785 | ▲9.229 |
| Interest Coverage Ratio | 53.243 | ▲10.001 | ▲13.378 |
| Short Term Operating Cash Flow Coverage Ratio | 133.492 | ▲48.522 | ▲42.028 |
| Operating Cash Flow Coverage Ratio | 0.136 | ▼-0.040 | ▼-0.045 |
| Capital Expenditure Coverage Ratio | 2.915 | ▲0.721 | ▼-0.231 |
| Dividend Paid And Capex Coverage Ratio | 2.713 | ▲0.694 | ▼-0.092 |
| Dividend Payout Ratio | 0.042 | ▼-0.004 | ▼-0.011 |
| Enterprise Value Multiple | 24.006 | ▲5.120 | ▲4.060 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $9.98B | $7.53B | $6.25B | $5.19B | $4.57B | |
| Enterprise value | $13.63B | $9.04B | $7.61B | $6.45B | $5.58B | |
| EV / Sales | 2.70x | 2.12x | 2.04x | 2.13x | 2.12x | |
| EV / Op. cash flow | 24.16x | 26.03x | 20.21x | 23.67x | 20.23x | |
| EV / Free cash flow | 36.78x | 47.83x | 28.14x | 34.87x | 27.06x | |
| EV / EBITDA | 24.01x | 18.89x | 21.55x | 17.90x | 17.39x | |
| Net debt / EBITDA | 6.43x | 3.15x | 3.85x | 3.49x | 3.13x | |
| Current ratio | 1.42x | 1.56x | 1.43x | 1.34x | 1.22x | |
| Income quality | 1.64x | 1.16x | 1.79x | 1.21x | 1.39x | |
| Graham number | $73 | $62 | $48 | $46 | $39 | |
| Graham net-net | -$38 | -$33 | -$32 | -$29 | -$24 | |
| Tax burden | 75.5% | 77.2% | 76.8% | 77.7% | 75.4% | |
| Interest burden | 98.3% | 97.9% | 97.1% | 97.0% | 97.4% | |
| Working capital | $378.0M | $414.2M | $312.2M | $199.1M | $116.6M | |
| Invested capital | $4.28B | $3.67B | $3.24B | $2.73B | $2.21B | |
| Return on assets | 6.3% | 6.4% | 5.0% | 6.5% | 6.8% | |
| Operating ROA | 8.4% | 8.1% | 6.7% | 9.4% | 9.7% | |
| Return on tangible assets | 6.4% | 6.5% | 5.1% | 6.7% | 7.0% | |
| Return on equity | 15.4% | 16.2% | 14.0% | 18.0% | 19.1% | |
| Return on invested capital | 6.9% | 6.9% | 5.6% | 7.8% | 8.4% | |
| Return on capital employed | 9.3% | 9.1% | 7.4% | 10.3% | 11.2% | |
| Earnings yield | 3.4% | 4.0% | 3.3% | 4.3% | 4.3% | |
| Free cash flow yield | 3.7% | 2.5% | 4.3% | 3.6% | 4.5% | |
| Capex / Op. cash flow | 34.3% | 45.6% | 28.2% | 32.1% | 25.2% | |
| Capex / Depreciation | 185.5% | 188.1% | 146.7% | 140.4% | 124.2% | |
| Capex / Sales | 3.8% | 3.7% | 2.8% | 2.9% | 2.6% | |
| SG&A / Sales | 5.3% | 5.3% | 7.1% | 5.2% | 5.8% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.0% | 0.9% | 0.8% | 0.8% | 0.7% | |
| Intangibles / Total assets | 1.9% | 2.3% | 2.0% | 2.4% | 2.3% | |
| Days sales outstanding | 46d | 49d | 47d | 49d | 46d | |
| Days payables outstanding | 8d | 10d | 11d | 11d | 10d | |
| Operating cycle | 46d | 49d | 47d | 49d | 46d | |
| Cash conversion cycle | 38d | 39d | 37d | 38d | 36d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-19 Kaplan Fox Notifies The Ensign Group, Inc. (NASDAQ: ENSG) Investors of a Securities Class Action Deadline on December 7, 2026 NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Ensign Group, Inc. (“Ensign” or the “Company”) (NASDAQ: ENSG) on behalf of investors that purchased or otherwise acquired Ensign securities between February 10, 2022 and June 18, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Ensign and have suffered losses, you may CLICK HERE to contact us.
- 2026-10-19 Bronstein, Gewirtz & Grossman LLC Urges The Ensign Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - October 19, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
- 2026-10-19 Shareholders who lost money in shares of The Ensign Group, Inc. (NASDAQ: ENSG) should contact Wolf Haldenstein Immediately NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed against The Ensign Group, Inc. (“Ensign” or the “Company”) (NASDAQ: ENSG) on behalf of investors that purchased or otherwise acquired Ensign securities between February 10, 2022 and June 18, 2026 (the Class Period). Investors who purchased Ensign shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for December 7, 2026.
- 2026-10-19 The Ensign Group Is Healthy, But Not Worth Buying The Ensign Group benefits from demographic tailwinds and has delivered robust top- and bottom-line growth across its skilled nursing and senior living operations. ENSG expanded its operational footprint, increasing skilled nursing beds from 30,602 to 40,711 and facilities from 297 to 396 since 2023, driving higher occupancy and profitability. Standard Bearer, ENSG''s REIT segment, delivers outsized profit contribution relative to revenue and remains a strategic focus for expansion.
- 2026-10-19 Bronstein, Gewirtz & Grossman LLC Urges The Ensign Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against The Ensign Group, Inc. (NASDAQ: ENSG) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ensign securities between February 10, 2022 and June 18, 2026, both dates inclusive (the “Class Period”).
- 2026-10-19 ENSG Deadline Reminder: Ensign Group Investors are Notified to Contact BFA Law before the Expiration of the December 7 Lead Plaintiff Deadline NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Ensign Group, Inc. (NASDAQ:ENSG) and certain of the company''s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.
- 2026-10-19 Kaplan Fox Advises The Ensign Group, Inc. (ENSG) Investors to Act Before the Lead Plaintiff Deadline on December 7, 2026 New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG) on behalf of investors that purchased or otherwise acquired Ensign securities between February 10, 2022 and June 18, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Ensign and have suffered losses, you may CLICK HERE to contact us.
- 2026-10-18 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages The Ensign Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ENSG New York, New York--(Newsfile Corp. - October 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 2026-10-17 ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Ensign Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ENSG New York, New York--(Newsfile Corp. - October 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 2026-10-17 ROSEN, THE FIRST FILING FIRM, Encourages The Ensign Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ENSG NEW YORK, Oct. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed.